Stable pH optimized formulation of a modified antibody
申请人:——
公开号:US20040091490A1
公开(公告)日:2004-05-13
The present invention is directed to stable formulations of modified antibodies, each comprising an antibody fragment in an aqueous solution covalently attached to at least one nonproteinaceous polymer, such as poly(ethyleneglycol), through a succinimide moiety. CDP870 is an example of one such modified antibody. The formulations of the present invention include a buffer that maintains the solution at a pH of 3.5 to about 6, wherein all components of the modified antibody, including a succinimide ring of the succinimide moiety, are stable.
[EN] STABLE PH OPTIMIZED FORMULATION OF A MODIFIED ANTIBODY<br/>[FR] PREPARATION OPTIMISEE A PH STABLE D'ANTICORPS MODIFIE
申请人:PHARMACIA CORP
公开号:WO2004019861A2
公开(公告)日:2004-03-11
The present invention is directed to stable formulations of modified antibodies, each comprising an antibody fragment in an aqueous solution covalently attached to at least one nonproteinaceous polymer, such as @>lC(ethyleneglycol), through 0 succinimide moiety. CDP870 is an example of one such modified antibody. The formulations of the present invention include 0 buffer that maintains the solution at 0 pH of 3.5 to about 6, wherein all components of the modified antibody, including 0 succinimide ring of the succinimide moiety, are stable.
Paul; Tchelitcheff, Bulletin de la Societe Chimique de France, 1948, p. 197,202